Hanmi Pharma to move up launch of anti-obesity drug

Quick Summary:

Hanmi Pharmaceutical stated that the drug is expected to offer weight-loss effects comparable to Wegovy, a leading GLP-1 obesity treatment while providing superior cardiovascular and kidney protection compared to other GLP-1-based therapies.

Utilizing Hanmi Pharmaceutical's Lapscovery platform technology, efpeglenatide employs a slow absorption mechanism, allowing the drug to be gradually released in the body, thereby reducing gastrointestinal side effects commonly associated with GLP-1 medications.

South Korea’s Hanmi Pharmaceutical Co.announced on Thursday the launch of its anti-obesity drug candidate efpeglenatide has been rescheduled to the second half of 2026, earlier than originally planned.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: Economy

Markets: South Korea

Topics: Drug Patient Company Glp-1 Obesity Pharmaceutical Effects Hanmi Digital Efpeglenatide Treatment

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-11-21 @ 16:49:57 (3 hours ago)

News Timezone: GMT +8:00

News Source URL: kedglobal.com

Language: English

Article Length: 184 words

Reading Time: 2 minutes read

Sentences: 12 lines

Sentence Length: 16 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Korea Economic Daily

News ID: 23732867

View Article Analysis

About Korea Economic Daily

Main Topics: Economy

Official Website: kedglobal.com

Update Frequency: 15 posts per day

Year Established: 1964

Headquarters: South Korea

News Last Updated: 11 minutes ago

Coverage Areas: South Korea

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #91

Publisher Details

Frequently Asked Questions